Arcutis Biotherapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

ARQT$27.39+4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

ARCUTIS BIOTHERAPEUTICS, INC.Condensed Consolidated Statements of Changes in Stockholders’ Equity(In thousands)(unaudited)
Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · Total Stockholders’ Equity
Shares · Amount
Balance—December 31, 2024	117,848	$12	$1,279,479	$(7)	$(1,121,943)	$157,541
Issuance of common stock upon the exercise of stock options	110	—	395	—	—	395
Issuance of common stock upon the vesting of restricted stock units	1,180	—	—	—	—	—
Stock-based compensation expense	—	—	9,915	—	—	9,915
Unrealized loss on marketable securities	—	—	—	(137)	—	(137)
Foreign currency translation adjustment	—	—	—	4	—	4
Net loss	—	—	—	—	(25,060)	(25,060)
Balance—March 31, 2025	119,138	12	1,289,789	(140)	(1,147,003)	142,658
Issuance of common stock upon the exercise of stock options	19	—	61	—	—	61
Issuance of common stock upon the vesting of restricted stock units	522	—	—	—	—	—
Shares issued pursuant to the employee stock purchase plan	119	—	1,319	—	—	1,319
Stock-based compensation expense	—	—	10,717	—	—	10,717
Unrealized loss on marketable securities	—	—	—	(95)	—	(95)
Foreign currency translation adjustment	—	—	—	200	—	200
Net loss	—	—	—	—	(15,886)	(15,886)
Balance—June 30, 2025	119,798	$12	$1,301,886	$(35)	$(1,162,889)	$138,974

ARCUTIS BIOTHERAPEUTICS, INC.Condensed Consolidated Statements of Changes in Stockholders’ Equity(In thousands)(unaudited)
Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · Total Stockholders’ Equity
Shares · Amount
Balance—December 31, 2023	96,787	$9	$1,070,558	$4	$(981,904)	$88,667
Issuance of shares of common stock net of discount and issuance costs of $10,820	18,158	3	161,679	—	—	161,682
Issuance of common stock upon the exercise of stock options	22	—	82	—	—	82
Issuance of common stock upon the vesting of restricted stock units	538	—	—	—	—	—
Stock-based compensation expense	—	—	10,030	—	—	10,030
Unrealized loss on marketable securities	—	—	—	(116)	—	(116)
Foreign currency translation adjustment	—	—	—	(21)	—	(21)
Net loss	—	—	—	—	(35,382)	(35,382)
Balance—March 31, 2024	115,505	12	1,242,349	(133)	(1,017,286)	224,942
Issuance of common stock upon the exercise of stock options	147	—	806	—	—	806
Issuance of common stock upon the vesting of restricted stock units	443	—	—	—	—	—
Shares issued pursuant to the employee stock purchase plan	384	—	649	—	—	649
Stock-based compensation expense	—	—	12,523	—	—	12,523
Unrealized loss on marketable securities	—	—	—	(127)	—	(127)
Foreign currency translation adjustment	—	—	—	(34)	—	(34)
Net loss	—	—	—	—	(52,332)	(52,332)
Balance—June 30, 2024	116,479	$12	$1,256,327	$(294)	$(1,069,618)	$186,427

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.